ELELYSO (pronounced Eh-leh-LYE-SO) is indicated for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is supplied as 200 Units per vial and is available by prescription only.

ELELYSO™ (taliglucerase alfa) This product information is intended only for residents of the United States. for Consumers: Visit www.elelyso.com; ELELYSO - U.S. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources; for Healthcare professionals: ELELYSO U.S. Physician Prescribing Information

Taliglucerase alfa, sold under the brand name Elelyso among others, is a biopharmaceutical medication developed by Protalix and Pfizer. [3] [4] [full citation needed] The drug, a recombinant glucocerebrosidase used to treat Gaucher's disease, is the first plant-made pharmaceutical to win approval by the U.S. Food and Drug Administration (FDA).

2014年11月24日 · ELELYSO™注射液作为酶替代疗法（enzymereplacementtherapy，ERT），用于I型戈谢病 (Gaucher disease，旧称高雪氏病，主要症状包括肝脏或脾脏损害、红细胞数降低（贫血）、血小板数降低和骨骼疾病)成年患者的长期治疗，每隔一周注射一次。 这也向投资者和企业发出了一个清晰而积极的信号，利用植物细胞制造药物具有十分广阔的前景和市场价值。 同时，相较于动物细胞培养的类似药，更为廉价的Elelyso成为了戈谢病患者新的福音。 ELELYSO™ …

ELELYSO, an enzyme replacement therapy, is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside.

Learn about ELELYSO® (taliglucerase alfa) for injection, for treatment of Type 1 Gaucher disease in adults and children. See risks and benefits of ELELYSO®.

ELELYSOTM (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed...

2024年11月21日 · Elelyso is a man-made form of an enzyme that occurs naturally in the body. It is used as an enzyme replacement in adults and children at least 4 years old with Type I Gaucher disease. Gaucher disease is a genetic condition in which the body lacks the enzyme needed to break down certain fatty materials (lipids).

Elelyso ® (taliglucerase alfa) is an Enzyme Replacement Therapy (ERT), replacing the deficient glucocerebrosidase enzyme with a recombinant form of the protein. Taliglucerase alfa is the company’s first approved drug product produced through ProCellEx ® and the first plant cell-based recombinant therapeutic protein approved by the FDA or ...

2025年3月13日 · Elelyso (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of type 1 Gaucher disease. What Are Side Effects of Elelyso? Elelyso may cause serious side effects including: